Abstract
Tumors are most frequently induced by environmental factors with oncogenic potential. Beside tumor cells, cancer tissue contains several nonmalignant cells with well-defined function, embedded into the acellular extracellular matrix playing an important role in tumor progression. The extracellular matrix (ECM) is an indispensable element of all tissues which can modulate cell growth, survival, migration, immune response, and drug resistance. Among its main molecular components are glycosaminoglycans (GAGs) and proteoglycans (PGs), which have been shown to play fundamental roles either in physiological or malignant tissue. An important GAG of the ECM in the tumor microenvironment (TME) is hyaluronic acid, whose synthesis and degradation are altered in a variety of tumors. The biological effects of the abnormal accumulation of HA and the subsequent remodeling of the associated ECM differ according to the type of tumor. In this sense, the ECM-derived HA biological effects in different types of tumors are discussed below in this chapter. Additionally, we make it clear that approaches that interfere with HA metabolism may be a potential therapeutic approach for the treatment of cancer.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Similar content being viewed by others
References
Akiyama Y, Jung S, Salhia B et al (2001) Hyaluronate receptors mediating glioma cell migration and proliferation. J Neurooncol 53:115–127. https://doi.org/10.1023/A:1012297132047
Alaniz L, García M, Cabrera P et al (2004) Modulation of matrix metalloproteinase-9 activity by hyaluronan is dependent on NF-κB activity in lymphoma cell lines with dissimilar invasive behavior. Biochem Biophys Res Commun 324:736–743. https://doi.org/10.1016/j.bbrc.2004.09.120
Amanzadeh A, Heidarnejad F, Abdollahpour-Alitappeh M et al (2017) Development of high-affinity monoclonal antibody using CD44 overexpressed cells as a candidate for targeted immunotherapy and diagnosis of acute myeloid leukemia. Hum Antibodies 26:7–15. https://doi.org/10.3233/HAB-170315
Amoroso MR, Matassa DS, Agliarulo I et al (2017) Stress-adaptive response in ovarian cancer drug resistance. Adv Protein Chem Struct Biol 108:163–198
Anagnostopoulou E, Papanastasopoulou C, Papastamataki M et al (2017) Serum hyaluronic acid levels are altered in acute leukemia patients: potential prognostic implications. Acta Haematol 138:44–51. https://doi.org/10.1159/000477574
Anjum K, Shagufta BI, Abbas SQ et al (2017) Current status and future therapeutic perspectives of glioblastoma multiforme (GBM) therapy: a review. Biomed Pharmacother 92:681–689. https://doi.org/10.1016/j.biopha.2017.05.125
Anttila MA, Tammi RH, Tammi MI et al (2000) High levels of stromal hyaluronan predict poor disease outcome in epithelial ovarian cancer. Cancer Res 60
Apperley JF (2015) Chronic myeloid leukaemia. Lancet 385:1447–1459. https://doi.org/10.1016/S0140-6736(13)62120-0
Arai E, Nishida Y, Wasa J et al (2011) Inhibition of hyaluronan retention by 4-methylumbelliferone suppresses osteosarcoma cells in vitro and lung metastasis in vivo. Br J Cancer 105:1839–1849. https://doi.org/10.1038/bjc.2011.459
Arnold JM, Gu F, Ambati CR et al (2020) UDP-glucose 6-dehydrogenase regulates hyaluronic acid production and promotes breast cancer progression. Oncogene 39:3089–3101. https://doi.org/10.1038/s41388-019-0885-4
Auvinen P, Tammi R, Parkkinen J et al (2000) Hyaluronan in peritumoral stroma and malignant cells associates with breast cancer spreading and predicts survival. Am J Pathol 156:529–536. https://doi.org/10.1016/S0002-9440(10)64757-8
Avigdor A (2004) CD44 and hyaluronic acid cooperate with SDF-1 in the trafficking of human CD34+ stem/progenitor cells to bone marrow. Blood 103:2981–2989. https://doi.org/10.1182/blood-2003-10-3611
Baumgartner G, Gomar-Höss C, Sakr L et al (1998) The impact of extracellular matrix on the chemoresistance of solid tumors—Experimental and clinical results of hyaluronidase as additive to cytostatic chemotherapy. Cancer Lett 131(1):85–99
Bavaro L, Martelli M, Cavo M, Soverini S (2019) Mechanisms of disease progression and resistance to tyrosine kinase inhibitor therapy in chronic myeloid leukemia: an update. Int J Mol Sci 20:6141. https://doi.org/10.3390/ijms20246141
Bertrand P, Courel MN, Maingonnat C et al (2005) Expression of HYAL2 mRNA, hyaluronan and hyaluronidase in B-cell non-Hodgkin lymphoma: relationship with tumor aggressiveness. Int J Cancer 113:207–212. https://doi.org/10.1002/ijc.20562
Bharadwaj AG, Kovar JL, Loughman E et al (2009) Spontaneous metastasis of prostate cancer is promoted by excess hyaluronan synthesis and processing. Am J Pathol 174:1027–1036. https://doi.org/10.2353/ajpath.2009.080501
Bjorklund CC, Baladandayuthapani V, Lin HY et al (2014) Evidence of a role for CD44 and cell adhesion in mediating resistance to lenalidomide in multiple myeloma: therapeutic implications. Leukemia 28(2):373–383. https://doi.org/10.1038/leu.2013.174
Bjorklund CC, Kang J, Amatangelo M et al (2019) Iberdomide (CC-220) is a potent cereblon E3 ligase modulator with antitumor and immunostimulatory activities in lenalidomide- and pomalidomide-resistant multiple myeloma cells with dysregulated CRBN. Leukemia 34(4):1197–1201. https://doi.org/10.1038/s41375-019-0620-8
Bono P, Rubin K, Higgins JMG, Hynes RO (2001) Layilin, a novel integral membrane protein, is a hyaluronan receptor. Mol Biol Cell 12:891–900. https://doi.org/10.1091/mbc.12.4.891
Bouguignon LYW (2009) Hyaluronan-mediated CD44 interaction with receptor and non-receptor kinases promotes oncogenic signaling, cytoskeleton activation and tumor progression. Hyaluronan Cancer Biol 89–107. https://doi.org/10.1016/B978-012374178-3.10006-7
Bourguignon LYW (2008) Hyaluronan-mediated CD44 activation of RhoGTPase signaling and cytoskeleton function promotes tumor progression. Semin Cancer Biol 18:251–259. https://doi.org/10.1016/j.semcancer.2008.03.007
Brenner H, Kloor M, Pox CP (2014) Colorectal cancer. Lancet 383:1490–1502. https://doi.org/10.1016/S0140-6736(13)61649-9
Brett M-E, Bomberger HE, Doak GR et al (2018) In vitro elucidation of the role of pericellular matrix in metastatic extravasation and invasion of breast carcinoma cells. Integr Biol 10:242–252. https://doi.org/10.1039/c7ib00173h
Breyer R, Hussein S, Radu DL et al (2000) Disruption of intracerebral progression of C6 rat glioblastoma by in vivo treatment with anti-CD44 monoclonal antibody. J Neurosurg 92:140–149. https://doi.org/10.3171/jns.2000.92.1.0140
Bullard KM, Kim HR, Wheeler MA et al (2003) Hyaluronan synthase-3 is upregulated in metastatic colon carcinoma cells and manipulation of expression alters matrix retention and cellular growth. Int J Cancer 107:739–746. https://doi.org/10.1002/ijc.11475
Burgstaller G, Oehrle B, Gerckens M et al (2017) The instructive extracellular matrix of the lung: basic composition and alterations in chronic lung disease. Eur Respir J 50. https://doi.org/10.1183/13993003.01805-2016
Celegato M, Borghese C, Casagrande N et al (2014) Bortezomib down-modulates the survival factor interferon regulatory factor 4 in Hodgkin lymphoma cell lines and decreases the protective activity of Hodgkin lymphoma-associated fibroblasts. Leuk Lymphoma 55:149–159. https://doi.org/10.3109/10428194.2013.800196
Chanmee T, Ontong P, Itano N (2016) Hyaluronan: a modulator of the tumor microenvironment. Cancer Lett 375:20–30. https://doi.org/10.1016/j.canlet.2016.02.031
Cheng X, Kohi S, Koga A et al (2016) Hyaluronan stimulates pancreatic cancer cell motility. Oncotarget 7:4829–4840. https://doi.org/10.18632/oncotarget.6617
Chetty C, Vanamala SK, Gondi CS et al (2012) MMP-9 induces CD44 cleavage and CD44 mediated cell migration in glioblastoma xenograft cells. Cell Signal 24:549–559. https://doi.org/10.1016/j.cellsig.2011.10.008
Chintala SK, Gokaslan ZL, Go Y et al (1996) Role of extracellular matrix proteins in regulation of human glioma cell invasion in vitro. Clin Exp Metastasis 14:358–366. https://doi.org/10.1007/BF00123395
Clift R, Souratha J, Garrovillo SA et al (2019) Remodeling the tumor microenvironment sensitizes breast tumors to anti-programmed death-ligand 1 immunotherapy. Cancer Res 79:4149–4159. https://doi.org/10.1158/0008-5472.CAN-18-3060
Collins RJ, Verschuer LA, Harmon B et al (1989) Spontaneous programmed death (apoptosis) of B-chronic lymphocytic leukaemia cells following their culture in vitro. Br J Haematol 71:343–350. https://doi.org/10.1111/j.1365-2141.1989.tb04290.x
Colombo N, van Gorp T, Parma G et al (2006) Ovarian cancer. Crit Rev Oncol Hematol 60:159–179. https://doi.org/10.1016/j.critrevonc.2006.03.004
Colombo N, Lorusso D, Scollo P (2017) Impact of recurrence of ovarian cancer on quality of life and outlook for the future. Int J Gynecol Cancer 27:1134–1140. https://doi.org/10.1097/IGC.0000000000001023
Cook G, Dumbar M, Franklin IM (1997) The role of adhesion molecules in multiple myeloma. Acta Haematol 97:81–89. https://doi.org/10.1159/000203663
Corte MD, González LO, Junquera S et al (2010) Analysis of the expression of hyaluronan in intraductal and invasive carcinomas of the breast. J Cancer Res Clin Oncol 136:745–750. https://doi.org/10.1007/s00432-009-0713-2
Costa F, Dalla Palma B, Giuliani N (2019) CD38 expression by myeloma cells and its role in the context of bone marrow microenvironment: modulation by therapeutic agents. Cell 8. https://doi.org/10.3390/cells8121632
Cowman MK, Lee H-G, Schwertfeger KL et al (2015) The content and size of hyaluronan in biological fluids and tissues. Front Immunol 6. https://doi.org/10.3389/fimmu.2015.00261
Csoka AB, Stern R (2013) Hypotheses on the evolution of hyaluronan: a highly ironic acid. Glycobiology 23:398–411. https://doi.org/10.1093/glycob/cws218
Cyphert JM, Trempus CS, Garantziotis S (2015) Size matters: molecular weight specificity of hyaluronan effects in cell biology. Int J Cell Biol 2015:1–8. https://doi.org/10.1155/2015/563818
Dahl IMS, Rasmussen T, Kauric G, Husebekk A (2002) Differential expression of CD56 and CD44 in the evolution of extramedullary myeloma. Br J Haematol 116:273–277. https://doi.org/10.1046/j.1365-2141.2002.03258.x
Das R, Strowig T, Verma R, Koduru S, Hafemann A, Hopf S et al (2016) Microenvironment dependent growth of preneoplastic and malignant plasma cells in humanized mice. Nat Med 22(11):1351–1357
dela Cruz CS, Tanoue LT, Matthay RA (2011) Lung cancer: epidemiology, etiology, and prevention. Clin Chest Med 32:605–644. https://doi.org/10.1016/j.ccm.2011.09.001
Delpech B, Maingonnat C, Girard N et al (1993) Hyaluronan and hyaluronectin in the extracellular matrix of human brain tumour stroma. Eur J Cancer 29:1012–1017. https://doi.org/10.1016/S0959-8049(05)80214-X
Dufort CC, DelGiorno KE, Carlson MA et al (2016a) Interstitial pressure in pancreatic ductal adenocarcinoma is dominated by a gel-fluid phase. Biophys J 110:2106–2119. https://doi.org/10.1016/j.bpj.2016.03.040
Dufort CC, Delgiorno KE, Hingorani SR (2016b) Mounting pressure in the microenvironment: fluids, solids, and cells in pancreatic ductal adenocarcinoma. Gastroenterology 150:1545–1557.e2
Eberth S, Schneider B, Rosenwald A et al (2010) Epigenetic regulation of CD44 in Hodgkin and non-Hodgkin lymphoma. BMC Cancer 10:1–14. https://doi.org/10.1186/1471-2407-10-517
Eikenes L, Tari M, Tufto I et al (2005) Hyaluronidase induces a transcapillary pressure gradient and improves the distribution and uptake of liposomal doxorubicin (Caelyx™) in human osteosarcoma xenografts. Br J Cancer 93(1):81–88. https://doi.org/10.1038/sj.bjc.6602626
Fhu CW, Graham AM, Yap CT et al (2014) Reed-Sternberg cell-derived lymphotoxin-a activates endothelial cells to enhance T-cell recruitment in classical Hodgkin lymphoma. Blood 124:2973–2982. https://doi.org/10.1182/blood-2014-05-576140
Fiegl M (2016) Epidemiology, pathogenesis, and etiology of acute leukemia. Handb Acute Leukemia 3–13. https://doi.org/10.1007/978-3-319-26772-2_2
Follini E, Marchesini M, Roti G (2019) Strategies to overcome resistance mechanisms in T-cell acute lymphoblastic leukemia. Int J Mol Sci 20:3021. https://doi.org/10.3390/ijms20123021
Funamoto Y, Nagai M, Haba R et al (2002) Hyaluronan synthesis by anaplastic large cell lymphoma with massive lymphomatous effusion: a case report. Acta Cytol 46:864–868. https://doi.org/10.1159/000327060
Garantziotis S, Savani RC (2019) Hyaluronan biology: a complex balancing act of structure, function, location and context. Matrix Biol 78–79:1–10. https://doi.org/10.1016/j.matbio.2019.02.002
García MG, Alaniz LD, Cordo Russo RI et al (2009) PI3K/Akt inhibition modulates multidrug resistance and activates NF-κB in murine lymphoma cell lines. Leuk Res 33. https://doi.org/10.1016/j.leukres.2008.06.010
García-Ortiz A, Rodríguez-García Y, Encinas J et al (2021) The role of tumor microenvironment in multiple myeloma development and progression. Cancer 13:217. https://doi.org/10.3390/cancers13020217
García-Peydró M, Fuentes P, Mosquera M et al (2018) The NOTCH1/CD44 axis drives pathogenesis in a T cell acute lymphoblastic leukemia model. J Clin Investig 128:2802–2818. https://doi.org/10.1172/JCI92981
Gesteira TF, Sun M, Coulson-Thomas YM et al (2017) Hyaluronan rich microenvironment in the limbal stem cell niche regulates limbal stem cell differentiation. Invest Ophthalmol Vis Sci 58:4407. https://doi.org/10.1167/IOVS.17-22326
Giannopoulos K, Mertens D, Bühler A et al (2009) The candidate immunotherapeutical target, the receptor for hyaluronic acid-mediated motility, is associated with proliferation and shows prognostic value in B-cell chronic lymphocytic leukemia. Leukemia 23(3):519–527. https://doi.org/10.1038/leu.2008.338
Girbl T, Hinterseer E, Grössinger EM et al (2013) CD40-mediated activation of chronic lymphocytic leukemia cells promotes their CD44-dependent adhesion to hyaluronan and restricts CCL21-induced motility. Cancer Res 73:561–570. https://doi.org/10.1158/0008-5472.CAN-12-2749
Gomez CS, Gomez P, Knapp J et al (2009) Hyaluronic acid and HYAL-1 in prostate biopsy specimens: predictors of biochemical recurrence. J Urol 182:1350–1356. https://doi.org/10.1016/J.JURO.2009.06.070
Goncharova V, Serobyan N, Iizuka S et al (2012) Hyaluronan expressed by the hematopoietic microenvironment is required for bone marrow hematopoiesis. J Biol Chem 287:25419–25433. https://doi.org/10.1074/jbc.M112.376699
González-Herrero I, Rodríguez-Hernández G, Luengas-Martínez A et al (2018) The making of leukemia. Int J Mol Sci 19. https://doi.org/10.3390/ijms19051494
Graham SM, Jørgensen HG, Allan E et al (2002) Primitive, quiescent, Philadelphia-positive stem cells from patients with chronic myeloid leukemia are insensitive to STI571 in vitro. Blood 99:319–325. https://doi.org/10.1182/blood.V99.1.319
Greiner J, Ringhoffer M, Taniguchi M et al (2002) Receptor for hyaluronan acid-mediated motility (RHAMM) is a new immunogenic leukemia-associated antigen in acute and chronic myeloid leukemia. Exp Hematol 30:1029–1035. https://doi.org/10.1016/S0301-472X(02)00874-3
Guerra C, Schuhmacher AJ, Cañamero M et al (2007) Chronic pancreatitis is essential for induction of pancreatic ductal adenocarcinoma by K-Ras oncogenes in adult mice. Cancer Cell 11:291–302. https://doi.org/10.1016/j.ccr.2007.01.012
Gul-Uludağ H, Valencia-Serna J, Kucharski C et al (2014) Polymeric nanoparticle-mediated silencing of CD44 receptor in CD34+ acute myeloid leukemia cells. Leuk Res 38:1299–1308. https://doi.org/10.1016/j.leukres.2014.08.008
Gutjahr JC, Greil R, Hartmann TN (2015) The role of CD44 in the pathophysiology of chronic lymphocytic leukemia. Front Immunol 6. https://doi.org/10.3389/FIMMU.2015.00177
Gutjahr JC, Bayer E, Yu X et al (2020) CD44 engagement enhances acute myeloid leukemia cell adhesion to the bone marrow microenvironment by increasing VLA-4 avidity. Haematologica 106. https://doi.org/10.3324/haematol.2019.231944
Gvozdenovic A, Arlt MJ, Campanile C et al (2013) CD44 enhances tumor formation and lung metastasis in experimental osteosarcoma and is an additional predictor for poor patient outcome. J Bone Miner Res 28:838–847. https://doi.org/10.1002/jbmr.1817
Hallek M, Shanafelt TD, Eichhorst B (2018) Chronic lymphocytic leukaemia. Lancet 391:1524–1537. https://doi.org/10.1016/S0140-6736(18)30422-7
Hamada S, Nishida Y, Zhuo L et al (2018) Suppression of hyaluronan synthesis attenuates the tumorigenicity of low-grade chondrosarcoma. J Orthop Res 36:1573–1580. https://doi.org/10.1002/jor.23794
Hamel KM, Liarski VM, Clark MR (2012) Germinal center B-cells. Autoimmunity 45:333–347
Hanke M, Hoffmann I, Christophis C et al (2014) Differences between healthy hematopoietic progenitors and leukemia cells with respect to CD44 mediated rolling versus adherence behavior on hyaluronic acid coated surfaces. Biomaterials 35:1411–1419. https://doi.org/10.1016/j.biomaterials.2013.11.011
Hartheimer JS, Park S, Rao SS, Kim Y (2019) Targeting hyaluronan interactions for glioblastoma stem cell therapy. Cancer Microenviron 12:47–56. https://doi.org/10.1007/s12307-019-00224-2
Heldin P, Basu K, Olofsson B et al (2013) Deregulation of hyaluronan synthesis, degradation and binding promotes breast cancer. J Biochem 154:395–408. https://doi.org/10.1093/jb/mvt085
Hidalgo M (2010) Pancreatic cancer. N Engl J Med 21:1605–1618. https://doi.org/10.1016/j.ccr.2012.04.025.Tumor-derived
Hiltunen ELJ, Anttila M, Kultti A et al (2002) Elevated hyaluronan concentration without hyaluronidase activation in malignant epithelial ovarian tumors. Cancer Res 62:6410–6413
Hong FS, Mitchell CA, Zantomio D (2010) Gelatinous transformation of the bone marrow as a late morphological change in imatinib mesylate treated chronic myeloid leukaemia. Pathology 42:84–85. https://doi.org/10.3109/00313020903434686
Horai T, Nakamura N, Tateishi R, Hattori S (1981) Glycosaminoglycans in human lung cancer. Cancer 48:2016–2021. https://doi.org/10.1002/1097-0142(19811101)48:9<2016::AID-CNCR2820480918>3.0.CO;2-A
Hosono K, Nishida Y, Knudson W et al (2007) Hyaluronan oligosaccharides inhibit tumorigenicity of osteosarcoma cell lines MG-63 and LM-8 in vitro and in vivo via perturbation of hyaluronan-rich pericellular matrix of the cells. Am J Pathol 171:274–286. https://doi.org/10.2353/ajpath.2007.060828
Hruban RH, Adsay NV, Albores-Saavedra J et al (2001) Pancreatic intraepithelial neoplasia: a new nomenclature and classification system for pancreatic duct lesions. Am J Surg Pathol 25:579–586. https://doi.org/10.1097/00000478-200105000-00003
Hu Y, Li S (2016) Survival regulation of leukemia stem cells. Cell Mol Life Sci 73:1039–1050. https://doi.org/10.1007/s00018-015-2108-7
Izzi V, Lakkala J, Devarajan R et al (2017) An extracellular matrix signature in leukemia precursor cells and acute myeloid leukemia. Haematologica 102:e245–e248. https://doi.org/10.3324/haematol.2017.167304
Jacobetz MA, Chan DS, Neesse A et al (2013) Hyaluronan impairs vascular function and drug delivery in a mouse model of pancreatic cancer. Gut 62:112–120. https://doi.org/10.1136/gutjnl-2012-302529
Jayson GC, Kohn EC, Kitchener HC, Ledermann JA (2014) Ovarian cancer. Lancet (London, England) 384:1376–1388. https://doi.org/10.1016/S0140-6736(13)62146-7
Karamanos NK, Theocharis AD, Piperigkou Z et al (2021) A guide to the composition and functions of the extracellular matrix. FEBS J. https://doi.org/10.1111/febs.15776
Karantanou C, Godavarthy PS, Krause DS (2018) Targeting the bone marrow microenvironment in acute leukemia. Leuk Lymphoma 59:2535–2545. https://doi.org/10.1080/10428194.2018.1434886
Karbownik MS, Pietras T, Szemraj J et al (2014) The ability of hyaluronan fragments to reverse the resistance of C6 rat glioma cell line to temozolomide and carmustine. Wspolczesna Onkologia 18:323–328. https://doi.org/10.5114/wo.2014.43493
Kartal-Yandim M, Adan-Gokbulut A, Baran Y (2016) Molecular mechanisms of drug resistance and its reversal in cancer. Crit Rev Biotechnol 36:716–726. https://doi.org/10.3109/07388551.2015.1015957
Kasai S, Furuichi Y, Ando N et al (2017) Inflammatory mediator ultra-low-molecular-weight hyaluronan triggers necrosis of B-precursor leukemia cells with high surface CD44 expression. Cell Death Dis 8:e2857–e2857. https://doi.org/10.1038/cddis.2017.249
Kato N, Shibata K, Uchigasaki S, Kurose A (2016) Relation between hyaluronan synthesis and cell morphology in ovarian clear cell carcinomas. Pathol Int 66:218–223. https://doi.org/10.1111/pin.12405
Katz B-Z (2010) Adhesion molecules—The lifelines of multiple myeloma cells. Semin Cancer Biol 20:186–195. https://doi.org/10.1016/j.semcancer.2010.04.003
Kaul A, Short WD, Wang X, Keswani SG (2021) Hyaluronidases in human diseases. Int J Mol Sci 22:1–11. https://doi.org/10.3390/IJMS22063204
Khaldoyanidi SK, Goncharova V, Mueller B, Schraufstatter IU (2014) Hyaluronan in the healthy and malignant hematopoietic microenvironment. Adv Cancer Res 123:149–189. https://doi.org/10.1016/B978-0-12-800092-2.00006-X
Kim HR, Wheeler MA, Wilson CM et al (2004) Hyaluronan facilitates invasion of colon carcinoma cells in vitro via interaction with CD44. Cancer Res 64:4569–4576. https://doi.org/10.1158/0008-5472.CAN-04-0202
Kim MS, Park MJ, Kim SJ et al (2005) Emodin suppresses hyaluronic acid-induced MMP-9 secretion and invasion of glioma cells. Int J Oncol 27:839–846. https://doi.org/10.3892/ijo.27.3.839
Kim YH, Lee SB, Shim S et al (2019) Hyaluronic acid synthase 2 promotes malignant phenotypes of colorectal cancer cells through transforming growth factor beta signaling. Cancer Sci 110:2226–2236. https://doi.org/10.1111/cas.14070
Klank RL, Decker Grunke SA, Bangasser BL et al (2017) Biphasic dependence of glioma survival and cell migration on CD44 expression level. Cell Rep 18:23–31. https://doi.org/10.1016/j.celrep.2016.12.024
Klein U, Dalla-Favera R (2008) Germinal centres: role in B-cell physiology and malignancy. Nat Rev Immunol 8:22–33
Kohli AG, Kivimäe S, Tiffany MR, Szoka FC (2014) Improving the distribution of Doxil® in the tumormatrix by depletion of tumor hyaluronan. J Control Release 191:105–114. https://doi.org/10.1016/j.jconrel.2014.05.019
Koike H, Nishida Y, Shinomura T et al (2020) Forced expression of KIAA1199, a novel hyaluronidase, inhibits tumorigenicity of low-grade chondrosarcoma. J Orthop Res 38:1942–1951. https://doi.org/10.1002/jor.24629
Kosaki R, Watanabe K, Yamaguchi Y (1999) Overproduction of hyaluronan by expression of the hyaluronan synthase Has2 enhances anchorage-independent growth and tumorigenicity. Cancer Res 59:1141
Krause DS, Lazarides K, von Andrian UH, van Etten RA (2006) Requirement for CD44 in homing and engraftment of BCR-ABL-expressing leukemic stem cells. Nat Med 12:1175–1180. https://doi.org/10.1038/nm1489
Kuang D-M, Wu Y, Chen N et al (2007) Tumor-derived hyaluronan induces formation of immunosuppressive macrophages through transient early activation of monocytes. Blood 110:587–595. https://doi.org/10.1182/blood-2007-01-068031
Kudo D, Suto A, Hakamada K (2017) The development of a novel therapeutic strategy to target hyaluronan in the extracellular matrix of pancreatic ductal adenocarcinoma. Int J Mol Sci 18
Kultti A, Pasonen-Seppänen S, Jauhiainen M et al (2009) 4-Methylumbelliferone inhibits hyaluronan synthesis by depletion of cellular UDP-glucuronic acid and downregulation of hyaluronan synthase 2 and 3. Exp Cell Res 315:1914–1923. https://doi.org/10.1016/j.yexcr.2009.03.002
Kuwabara H, Yoneda M, Nagai M et al (2003) High levels of hyaluronan production by a malignant lymphoma cell line with primary effusion lymphoma immunophenotype OHK. Br J Haematol 120:1055–1057. https://doi.org/10.1046/j.1365-2141.2003.04206.x
Lato MW, Przysucha A, Grosman S et al (2021) The new therapeutic strategies in pediatric T-cell acute lymphoblastic leukemia. Int J Mol Sci 22. https://doi.org/10.3390/ijms22094502
Laurent TC, Fraser JRE (1992) Hyaluronan 1. FASEB J 6:2397–2404. https://doi.org/10.1096/FASEBJ.6.7.1563592
Laurich C, Wheeler MA, Iida J et al (2004) Hyaluronan mediates adhesion of metastatic colon carcinoma cells. J Surg Res 122:70–74. https://doi.org/10.1016/j.jss.2004.05.018
Lengyel E (2010) Ovarian cancer development and metastasis. Am J Pathol 177:1053–1064. https://doi.org/10.2353/ajpath.2010.100105
le Rhun E, Preusser M, Roth P et al (2019) Molecular targeted therapy of glioblastoma. Cancer Treat Rev 80:101896. https://doi.org/10.1016/j.ctrv.2019.101896
Ley TJ, Miller C, Ding L et al (2013) Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia. N Engl J Med 368:2059–2074. https://doi.org/10.1056/NEJMoa1301689
Li Y, Li L, Brown TJ, Heldin P (2007) Silencing of hyaluronan synthase 2 suppresses the malignant phenotype of invasive breast cancer cells. Int J Cancer 120:2557–2567. https://doi.org/10.1002/ijc.22550
Lim EJ, Suh Y, Yoo KC et al (2017) Tumor-associated mesenchymal stem-like cells provide extracellular signaling cue for invasiveness of glioblastoma cells. Oncotarget 8:1438–1448. https://doi.org/10.18632/oncotarget.13638
Lin L-H, Chou H-C, Chang S-J et al (2020) Targeting UDP-glucose dehydrogenase inhibits ovarian cancer growth and metastasis. J Cell Mol Med 24:11883–11902. https://doi.org/10.1111/JCMM.15808
Lipponen P, Aaltomaa S, Tammi R, Tammi M, Ågren U, Kosma VM (2001) High stromal hyaluronan level is associated with poor differentiation and metastasis in prostate cancer. Eur J Cancer 37(7)
Llaneza A, Vizoso F, Rodríguez JC, Raigoso P, García-Muñiz JL, Allende MT, García Morán M (2000) Hyaluronic acid as prognostic marker in resectable colorectal cancer. Br J Surg 87(12):1690–1696
Lokeshwar VB, Lopez LE, Munoz D et al (2010) Antitumor activity of hyaluronic acid synthesis inhibitor 4-methylumbelliferone in prostate cancer cells. Cancer Res 70:2613–2623. https://doi.org/10.1158/0008-5472.CAN-09-3185
Lokeshwar VB, Mirza S, Jordan A (2014) Targeting hyaluronic acid family for cancer chemoprevention and therapy, 1st edn. Elsevier
Lokman NA, Price ZK, Hawkins EK et al (2019) 4-methylumbelliferone inhibits cancer stem cell activation and overcomes chemoresistance in ovarian cancer. Cancer 11. https://doi.org/10.3390/cancers11081187
Lompardía SL, Papademetrio DL, Mascaró M et al (2013) Human leukemic cell lines synthesize hyaluronan to avoid senescence and resist chemotherapy. Glycobiology 23:1463–1476. https://doi.org/10.1093/glycob/cwt074
Lompardía SL, Díaz M, Papademetrio DL et al (2016) Hyaluronan oligomers sensitize chronic myeloid leukemia cell lines to the effect of Imatinib. Glycobiology 26:343–352. https://doi.org/10.1093/glycob/cwv107
Lompardía SL, Díaz M, Papademetrio DL et al (2017) 4-methylumbelliferone and imatinib combination enhances senescence induction in chronic myeloid leukemia cell lines. Invest New Drugs 35:1–10. https://doi.org/10.1007/s10637-016-0397-9
Lompardía S, Díaz M, Pibuel M et al (2019) Hyaluronan abrogates imatinib-induced senescence in chronic myeloid leukemia cell lines. Sci Rep 9:10930. https://doi.org/10.1038/s41598-019-47248-8
Louis DN, Perry A, Reifenberger G et al (2016) The 2016 World Health Organization classification of tumors of the central nervous system: a summary. Acta Neuropathol 131:803–820. https://doi.org/10.1007/s00401-016-1545-1
Ma Y, Visser L, Roelofsen H et al (2008) Proteomics analysis of Hodgkin lymphoma: identification of new players involved in the cross-talk between HRS cells and infiltrating lymphocytes. Blood 111:2339–2346. https://doi.org/10.1182/blood-2007-09-112128
Makkar S, Riehl TE, Chen B et al (2019) Hyaluronic acid binding to TLR4 promotes proliferation and blocks apoptosis in colon cancer. Mol Cancer Ther 18:2446–2456. https://doi.org/10.1158/1535-7163.MCT-18-1225
Marchetti C, Pisano C, Facchini G et al (2010) First-line treatment of advanced ovarian cancer: current research and perspectives. Expert Rev Anticancer Ther 10:47–60. https://doi.org/10.1586/era.09.167
Maria BL, Gupta N, Gilg AG et al (2008) Targeting hyaluronan interactions in spinal cord astrocytomas and diffuse pontine gliomas. J Child Neurol 1214–1220
Martinez-Quintanilla J, He D, Wakimoto H et al (2015) Encapsulated stem cells loaded with hyaluronidase-expressing oncolytic virus for brain tumor therapy. Mol Ther 23:108–118. https://doi.org/10.1038/mt.2014.204
Means AL, Meszoely IM, Suzuki K et al (2005) Pancreatic epithelial plasticity mediated by acinar cell transdifferentiation and generation of nestin-positive intermediates. Development 132:3767–3776. https://doi.org/10.1242/dev.01925
Menghrajani K, Tallman MS (2018) New therapeutic strategies for high-risk acute myeloid leukemia. Curr Opin Hematol 25:90–94. https://doi.org/10.1097/MOH.0000000000000409
Monslow J, Govindaraju P, Puré E (2015) Hyaluronan—a functional and structural sweet spot in the tissue microenvironment. Front Immunol 6. https://doi.org/10.3389/FIMMU.2015.00231
Mooney KL, Choy W, Sidhu S et al (2016) The role of CD44 in glioblastoma multiforme. J Clin Neurosci 34:1–5. https://doi.org/10.1016/j.jocn.2016.05.012
Mulshine JL, Chow G, Tauler J (2010) Cytokines and growth factors stimulate hyaluronan production: role of hyaluronan in epithelial to mesenchymal-like transition in non-small cell lung cancer. J Biomed Biotechnol. https://doi.org/10.1155/2010/485468
Murugaiah V, Agostinis C, Varghese PM et al (2020) Hyaluronic acid present in the tumor microenvironment can negate the pro-apototic effect of a recombinant fragment of human surfactant protein D on breast cancer cells. Front Immunol 11:1171. https://doi.org/10.3389/fimmu.2020.01171
Nakagawa T, Kubota T, Kabuto M, Kodera T (1996) Hyaluronic acid facilitates glioma cell invasion in vitro. Anticancer Res 16:2917–2922
Nakamura R, Kuwabara H, Yoneda M et al (2007) Suppression of matrix metalloproteinase-9 by 4-methylumbelliferone. Cell Biol Int 31:1022–1026. https://doi.org/10.1016/j.cellbi.2007.03.016
Nakazawa H, Yoshihara S, Kudo D et al (2006) 4-methylumbelliferone, a hyaluronan synthase suppressor, enhances the anticancer activity of gemcitabine in human pancreatic cancer cells. Cancer Chemother Pharmacol 57:165–170. https://doi.org/10.1007/s00280-005-0016-5
Nikitovic D, Tzardi M, Berdiaki A et al (2015) Cancer microenvironment and inflammation: role of hyaluronan. Front Immunol 0:169. https://doi.org/10.3389/FIMMU.2015.00169
Nishida Y, Knudson W, Knudson CB, Ishiguro N (2005) Antisense inhibition of hyaluronan synthase-2 in human osteosarcoma cells inhibits hyaluronan retention and tumorigenicity. Exp Cell Res 307:194–203. https://doi.org/10.1016/j.yexcr.2005.03.026
Ohwada C, Nakaseko C, Koizumi M et al (2008) CD44 and hyaluronan engagement promotes dexamethasone resistance in human myeloma cells. Eur J Haematol 80:245–250. https://doi.org/10.1111/j.1600-0609.2007.01014.x
Onfroy-Roy L, Hamel D, Foncy J et al (2020) Extracellular matrix mechanical properties and regulation of the intestinal stem cells: when mechanics control fate. Cell 9:1–23. https://doi.org/10.3390/cells9122629
Orian-Rousseau V (2010) CD44, a therapeutic target for metastasising tumours. Eur J Cancer 46:1271–1277. https://doi.org/10.1016/j.ejca.2010.02.024
Palumbo A, Anderson K (2011) Multiple myeloma. N Engl J Med 364:1046–1060. https://doi.org/10.1056/NEJMra1011442
Perus LJM, Walsh LA, Walsh LA (2019) Microenvironmental heterogeneity in brain malignancies. Front Immunol 10:2294. https://doi.org/10.3389/fimmu.2019.02294
Philteos J, Karmur BS, Mansouri A (2019) MGMT testing in glioblastomas pitfalls and opportunities. Am J Clin Oncol 42:117–122. https://doi.org/10.1097/COC.0000000000000490
Pibuel MA, Díaz M, Molinari Y et al (2021a) 4-Methylumbelliferone as a potent and selective antitumor drug on a glioblastoma model. Glycobiology 31:29–43. https://doi.org/10.1093/glycob/cwaa046
Pibuel MA, Poodts D, Díaz M et al (2021b) The scrambled story between hyaluronan and glioblastoma. J Biol Chem 296
Pirinen R, Tammi R, Tammi M et al (2001) Prognostic value of hyaluronan expression in non-small-cell lung cancer: increased stromal expression indicates unfavorable outcome in patients with adenocarcinoma. Int J Cancer 95. https://doi.org/10.1002/1097-0215(20010120)95:1<12::AID-IJC1002>3.0.CO;2-E
Ponta H, Sherman L, Herrlich PA (2003) CD44: from adhesion molecules to signalling regulators. Nat Rev Mol Cell Biol 4(4):33–45. https://doi.org/10.1038/nrm1004
Posey JT, Soloway MS, Ekici S, Sofer M, Civantos F, Duncan RC, Lokeshwar VB (2003) Evaluation of the prognostic potential of hyaluronic acid and hyaluronidase (HYAL1) for prostate cancer. Cancer Res 63(10):2638–2644
Provenzano PP, Cuevas C, Chang AE et al (2012) Enzymatic targeting of the stroma ablates physical barriers to treatment of pancreatic ductal adenocarcinoma. Cancer Cell 21:418–429. https://doi.org/10.1016/j.ccr.2012.01.007
Radotra B, McCormick D (1997) Glioma invasion in vitro is mediated by CD44–hyaluronan interactions. J Pathol 181:434–438. https://doi.org/10.1002/(SICI)1096-9896(199704)181:4<434::AID-PATH797>3.0.CO;2-S
Rajaratnam V, Islam MM, Yang M et al (2020) Glioblastoma: pathogenesis and current status of chemotherapy and other novel treatments. Cancer 12:937. https://doi.org/10.3390/cancers12040937
Rajkumar SV, Dimopoulos MA, Palumbo A et al (2014) International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma. Lancet Oncol 15:e538–e548. https://doi.org/10.1016/S1470-2045(14)70442-5
Rangel MP, de Sá VK, Martins V et al (2015) Tissue hyaluronan expression, as reflected in the sputum of lung cancer patients, is an indicator of malignancy. Braz J Med Biol Res 48:557–567. https://doi.org/10.1590/1414-431X20144300
Renyi-Vamos F, Tovari J, Fillinger J et al (2005) Lymphangiogenesis correlates with lymph node metastasis, prognosis, and angiogenic phenotype in human non-small cell lung cancer. Clin Cancer Res 11:7344–7353. https://doi.org/10.1158/1078-0432.CCR-05-1077
Riehl TE, Ee X, Stenson WF (2012) Hyaluronic acid regulates normal intestinal and colonic growth in mice. Am J Physiol Gastrointest Liver Physiol 303:377–388. https://doi.org/10.1152/ajpgi.00034.2012
Riehl TE, Santhanam S, Foster L et al (2015) CD44 and TLR4 mediate hyaluronic acid regulation of Lgr5+ stem cell proliferation, crypt fission, and intestinal growth in postnatal and adult mice. Am J Physiol Gastrointest Liver Physiol 309:G874–G887. https://doi.org/10.1152/ajpgi.00123.2015
Ropponen K, Tammi M, Parkkinen J, Eskelinen M, Tammi R, Lipponen P et al (1998) Tumor cell-associated hyaluronan as an unfavorable prognostic factor in colorectal cancer. Cancer Res 58(2):342–347
Rui Kang DT (2012) Autophagy in pancreatic cancer pathogenesis and treatment—PubMed. Am J Cancer Res 2:383–396
Russo RIC, García MG, Alaniz L et al (2008) Hyaluronan oligosaccharides sensitize lymphoma resistant cell lines to vincristine by modulating P-glycoprotein activity and PI3K/Akt pathway. Int J Cancer 122:1012–1018. https://doi.org/10.1002/ijc.23122
Sadeghi N, Camby I, Goldman S et al (2003) Effect of hydrophilic components of the extracellular matrix on quantifiable diffusion-weighted imaging of human gliomas: preliminary results of correlating apparent diffusion coefficient values and hyaluronan expression level. Am J Roentgenol 181:235–241. https://doi.org/10.2214/ajr.181.1.1810235
Sato N, Kohi S, Hirata K, Goggins M (2016) Role of hyaluronan in pancreatic cancer biology and therapy: once again in the spotlight. Cancer Sci 107:569–575
Schepers K, Pietras EM, Reynaud D et al (2013) Myeloproliferative neoplasia remodels the endosteal bone marrow niche into a self-reinforcing leukemic niche. Cell Stem Cell 13:285–299. https://doi.org/10.1016/j.stem.2013.06.009
Schepers K, Campbell TB, Passegué E (2015) Normal and leukemic stem cell niches: insights and therapeutic opportunities. Cell Stem Cell 16:254–267. https://doi.org/10.1016/J.STEM.2015.02.014
Schmitt M, Schmitt A, Rojewski MT et al (2008) RHAMM-R3 peptide vaccination in patients with acute myeloid leukemia, myelodysplastic syndrome, and multiple myeloma elicits immunologic and clinical responses. Blood 111:1357–1365. https://doi.org/10.1182/blood-2007-07-099366
Sener SF, Fremgen A, Menck HR, Winchester DP (1999) Pancreatic cancer: a report of treatment and survival trends for 100,313 patients diagnosed from 1985-1995, using the National Cancer Database. J Am Coll Surg 189:1–7. https://doi.org/10.1016/S1072-7515(99)00075-7
Shalini CNS, Suman FR, Jacob JS et al (2018) Prognostic significance of receptor for hyaluronan acid-mediated motility (CD168) in acute pediatric leukemias—assessment of clinical outcome, post induction, end of treatment and minimal residual disease. Hematol Transfus Cell Ther 40:310–316. https://doi.org/10.1016/j.htct.2018.01.008
Sharma C, Eltawil KM, Renfrew PD et al (2011) Advances in diagnosis, treatment and palliation of pancreatic carcinoma: 1990-2010. World J Gastroenterol 17:867–897. https://doi.org/10.3748/wjg.v17.i7.867
Shpilberg O, Jackisch C (2013) Subcutaneous administration of rituximab (MabThera) and trastuzumab (Herceptin) using hyaluronidase. Br J Cancer 109:1556–1561. https://doi.org/10.1038/bjc.2013.371
Siegel RL, Miller KD, Jemal A (2016) Cancer statistics, 2016. CA Cancer J Clin 66:7–30. https://doi.org/10.3322/caac.21332
Simioni C, Conti I, Varano G et al (2021) The complexity of the tumor microenvironment and its role in acute lymphoblastic leukemia: implications for therapies. Front Oncol 11:673506. https://doi.org/10.3389/fonc.2021.673506
Simpson MA, Lokeshwar VB (2008) Hyaluronan and hyaluronidase in genitourinary tumors. Front Biosci 13:5664
Simpson RML, Hong X, Wong MM et al (2016) Hyaluronan is crucial for stem cell differentiation into smooth muscle lineage. Stem Cells 34:1225–1238. https://doi.org/10.1002/STEM.2328
Slifka MK, Ahmed R (1998) Long-lived plasma cells: a mechanism for maintaining persistent antibody production. Curr Opin Immunol 10:252–258. https://doi.org/10.1016/s0952-7915(98)80162-3
Solis MA, Chen YH, Wong TY et al (2012) Hyaluronan regulates cell behavior: a potential niche matrix for stem cells. Biochem Res Int. https://doi.org/10.1155/2012/346972
Song JM, Im J, Nho RS et al (2019) Hyaluronan-CD44/RHAMM interaction-dependent cell proliferation and survival in lung cancer cells. Mol Carcinog 58:321–333. https://doi.org/10.1002/mc.22930
Stern R (2008) Hyaluronan in cancer biology. Semin Cancer Biol 18:237. https://doi.org/10.1016/j.semcancer.2008.04.001
Stern R, Jedrzejas MJ (2006) Hyaluronidases: their genomics, structures, and mechanisms of action. Chem Rev 106:818–839. https://doi.org/10.1021/cr050247k
Strobel H, Baisch T, Fitzel R et al (2019) Temozolomide and other alkylating agents in glioblastoma therapy. Biomedicine 69:1–17
Su W, Matsumoto S, Sorg B, Sherman LS (2019) Distinct roles for hyaluronan in neural stem cell niches and perineuronal nets. Matrix Biol 78–79:272–283. https://doi.org/10.1016/j.matbio.2018.01.022
Sundström G, Dahl IMS, Hultdin M et al (2005) Bone marrow hyaluronan distribution in patients with acute myeloid leukemia. Med Oncol 22:071–078. https://doi.org/10.1385/MO:22:1:071
Sundström G, Hultdin M, Engström-Laurent A, Dahl IMS (2010) Bone marrow hyaluronan and reticulin in patients with malignant disorders. Med Oncol 27:618–623. https://doi.org/10.1007/s12032-009-9257-1
Suto A, Kudo D, Yoshida E et al (2019) Increase of tumor infiltrating γδ T-cells in pancreatic ductal adenocarcinoma through remodeling of the extracellular matrix by a hyaluronan synthesis suppressor, 4-methylumbelliferone. Pancreas 48. https://doi.org/10.1097/MPA.0000000000001211
Tabarkiewicz J, Giannopoulos K (2010) Definition of a target for immunotherapy and results of the first peptide vaccination study in chronic lymphocytic leukemia. Transplant Proc 42:3293–3296. https://doi.org/10.1016/j.transproceed.2010.07.022
Tammi RH, Passi AG, Rilla K et al (2011) Transcriptional and post-translational regulation of hyaluronan synthesis. FEBS J 278:1419–1428. https://doi.org/10.1111/j.1742-4658.2011.08070.x
Tebbi CK (2021) Etiology of acute leukemia: a review. Cancers 13:2256. https://doi.org/10.3390/CANCERS13092256
Terwilliger T, Abdul-Hay M (2017) Acute lymphoblastic leukemia: a comprehensive review and 2017 update. Blood Cancer J 7:e577–e577. https://doi.org/10.1038/bcj.2017.53
Tian X, Azpurua J, Hine C et al (2013) High-molecular-mass hyaluronan mediates the cancer resistance of the naked mole rat. Nature 499(7458):346–349. https://doi.org/10.1038/nature12234
Till KJ, Zuzel M, Cawley JC (1999) The role of hyaluronan and interleukin 8 in the migration of chronic lymphocytic leukemia cells within lymphoreticular tissues. Cancer Res 59:4419
Tofuku K, Yokouchi M, Murayama T et al (2006) HAS3-related hyaluronan enhances biological activities necessary for metastasis of osteosarcoma cells. Int J Oncol 29:175–183. https://doi.org/10.3892/IJO.29.1.175
Toole BP (2002) Hyaluronan promotes the malignant phenotype. Glycobiology 12:37R–42R
Toole BP (2004) Hyaluronan: from extracellular glue to pericellular cue. Nat Rev Cancer 4(7):528–539. https://doi.org/10.1038/nrc1391
Toole BP (2009) Hyaluronan-CD44 interactions in cancer: paradoxes and possibilities. Clin Cancer Res 15
Toole BP, Hascall VC (2002) Hyaluronan and tumor growth. Am J Pathol 161:745–747
Toole BP, Slomiany MG (2008) Hyaluronan, CD44 and emmprin: partners in cancer cell chemoresistance. Drug Resist Updat 11:110–121. https://doi.org/10.1016/j.drup.2008.04.002
Tsatas D, Kanagasundaram V, Kaye A, Novak U (2002) EGF receptor modifies cellular responses to hyaluronan in glioblastoma cell lines. J Clin Neurosci 9:282–288. https://doi.org/10.1054/jocn.2001.1063
Urakawa H, Nishida Y, Wasa J et al (2012) Inhibition of hyaluronan synthesis in breast cancer cells by 4-methylumbelliferone suppresses tumorigenicity in vitro and metastatic lesions of bone in vivo. Int J Cancer 130:454–466. https://doi.org/10.1002/ijc.26014
Vacca A, di Loreto M, Ribatti D et al (1995) Bone marrow of patients with active multiple myeloma: angiogenesis and plasma cell adhesion molecules LFA-1, VLA-4, LAM-1, and CD44. Am J Hematol 50:9–14. https://doi.org/10.1002/ajh.2830500103
Vadillo E, Dorantes-Acosta E, Pelayo R, Schnoor M (2018) T cell acute lymphoblastic leukemia (T-ALL): new insights into the cellular origins and infiltration mechanisms common and unique among hematologic malignancies. Blood Rev 32:36–51. https://doi.org/10.1016/j.blre.2017.08.006
Valkonen M, Haapasalo H, Rilla K et al (2018) Elevated expression of hyaluronan synthase 2 associates with decreased survival in diffusely infiltrating astrocytomas. BMC Cancer 18:664. https://doi.org/10.1186/s12885-018-4569-1
van Oosterwijk JG, Herpers B, Meijer D et al (2012) Restoration of chemosensitivity for doxorubicin and cisplatin in chondrosarcoma in vitro: BCL-2 family members cause chemoresistance. Ann Oncol 23:1617–1626. https://doi.org/10.1093/annonc/mdr512
Vaughan S, Coward JI, Bast RC et al (2011) Rethinking ovarian cancer: recommendations for improving outcomes. Nat Rev Cancer 11:719–725. https://doi.org/10.1038/nrc3144
Vey N, Delaunay J, Martinelli G et al (2016) Phase I clinical study of RG7356, an anti-CD44 humanized antibody, in patients with acute myeloid leukemia. Oncotarget 7:32532–32542. https://doi.org/10.18632/oncotarget.8687
Vincent T, Mechti N (2004) IL-6 regulates CD44 cell surface expression on human myeloma cells. Leukemia 18:967–975. https://doi.org/10.1038/sj.leu.2403333
Virga J, Bognár L, Hortobágyi T et al (2017) Tumor grade versus expression of invasion-related molecules in astrocytoma. Pathol Oncol Res. https://doi.org/10.1007/s12253-017-0194-6
Vitale DL, Spinelli FM, del Dago D et al (2018) Co-treatment of tumor cells with hyaluronan plus doxorubicin affects endothelial cell behavior independently of VEGF expression. Oncotarget 9:36585–36602. https://doi.org/10.18632/oncotarget.26379
Wang C, Tammi M, Guo H, Tammi R (1996) Hyaluronan distribution in the normal epithelium of esophagus, stomach, and colon and their cancers. Am J Pathol 148:1861–1869
Wang TP, Pan YR, Fu CY, Chang HY (2010) Down-regulation of UDP-glucose dehydrogenase affects glycosaminoglycans synthesis and motility in HCT-8 colorectal carcinoma cells. Exp Cell Res 316:2893–2902. https://doi.org/10.1016/j.yexcr.2010.07.017
Wang D, Narula N, Azzopardi S et al (2016) Expression of the receptor for hyaluronic acid mediated motility (RHAMM) is associated with poor prognosis and metastasis in non-small cell lung carcinoma. Oncotarget 7:39957–39969. https://doi.org/10.18632/oncotarget.9554
Ween MP, Oehler MK, Ricciardelli C (2011) Role of versican, hyaluronan and CD44 in ovarian cancer metastasis. Int J Mol Sci 12:1009–1029
Wei X, Senanayake TH, Warren G, Vinogradov S, v. (2013) Hyaluronic acid-based nanogel-drug conjugates with enhanced anticancer activity designed for the targeting of cd44-positive and drug-resistant tumors. Bioconjug Chem 24:658–668. https://doi.org/10.1021/bc300632w
Wei J, Hu M, Huang K et al (2020) Roles of proteoglycans and glycosaminoglycans in cancer development and progression. Int J Mol Sci 21. https://doi.org/10.3390/ijms21175983
Weniger MA, Küppers R (2021) Molecular biology of Hodgkin lymphoma. Leukemia 35:968. https://doi.org/10.1038/S41375-021-01204-6
Willemen Y, van den Bergh JMJ, Bonte SM et al (2016) The tumor-associated antigen RHAMM (HMMR/CD168) is expressed by monocyte-derived dendritic cells and presented to T cells. Oncotarget 7:73960–73970. https://doi.org/10.18632/ONCOTARGET.12170
Witschen PM, Chaffee TS, Brady NJ et al (2020) Tumor cell associated hyaluronan-CD44 signaling promotes pro-tumor inflammation in breast cancer. Cancer 12. https://doi.org/10.3390/cancers12051325
Wong HH, Lemoine NR (2009) Pancreatic cancer: molecular pathogenesis and new therapeutic targets. Nat Rev Gastroenterol Hepatol 6:412–422. https://doi.org/10.1038/nrgastro.2009.89
Wong MCS, Huang J, Lok V et al (2021) Differences in incidence and mortality trends of colorectal cancer worldwide based on sex, age, and anatomic location. Clin Gastroenterol Hepatol 19:955–966.e61. https://doi.org/10.1016/j.cgh.2020.02.026
Yates TJ, Lopez LE, Lokeshwar SD et al (2015) Dietary supplement 4-methylumbelliferone: an effective chemopreventive and therapeutic agent for prostate cancer. J Natl Cancer Inst 107:1–10. https://doi.org/10.1093/jnci/djv085
Yoshida E, Kudo D, Nagase H et al (2016) Antitumor effects of the hyaluronan inhibitor 4-methylumbelliferone on pancreatic cancer. Oncol Lett 12:2337–2344. https://doi.org/10.3892/ol.2016.4930
Yousefi B, Zarghami N, Samadi N, Majidinia M (2016) Peroxisome proliferator-activated receptors and their ligands in cancer drug-resistance: opportunity or challenge. Anticancer Agents Med Chem 16:1541–1548. https://doi.org/10.2174/1871520616666160204112941
Zhang L, Underhill CB, Chen L (1995) Hyaluronan on the surface of tumor cells is correlated with metastatic behavior. Cancer Res 55:428–433
Zhang YE, Wei J, Wang H et al (2012) Epithelial mesenchymal transition correlates with CD24+CD44+ and CD133+ cells in pancreatic cancer. Oncol Rep 27:1599–1605. https://doi.org/10.3892/or.2012.1681
Zhang G, Lu R, Wu M et al (2019) Colorectal cancer-associated ~ 6 kDa hyaluronan serves as a novel biomarker for cancer progression and metastasis. FEBS J 286:3148–3163. https://doi.org/10.1111/febs.14859
Zhou H, Mak PY, Mu H et al (2017) Combined inhibition of β-catenin and Bcr–Abl synergistically targets tyrosine kinase inhibitor-resistant blast crisis chronic myeloid leukemia blasts and progenitors in vitro and in vivo. Leukemia 31:2065–2074. https://doi.org/10.1038/leu.2017.87
Zhu R, Wang SC, Sun C et al (2013) Hyaluronan-CD44 interaction promotes growth of decidual stromal cells in human first-trimester pregnancy. PLoS One 8. https://doi.org/10.1371/journal.pone.0074812
Zöller M (2015) CD44, hyaluronan, the hematopoietic stem cell, and leukemia-initiating cells. Front Immunol 6. https://doi.org/10.3389/FIMMU.2015.00235/FULL
Author information
Authors and Affiliations
Corresponding authors
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2022 The Author(s), under exclusive license to Springer Nature Switzerland AG
About this chapter
Cite this chapter
Icardi, A. et al. (2022). Hyaluronan in the Extracellular Matrix of Hematological and Solid Tumors. Its Biological Effects. In: Kovalszky, I., Franchi, M., Alaniz, L.D. (eds) The Extracellular Matrix and the Tumor Microenvironment. Biology of Extracellular Matrix, vol 11. Springer, Cham. https://doi.org/10.1007/978-3-030-99708-3_7
Download citation
DOI: https://doi.org/10.1007/978-3-030-99708-3_7
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-030-99707-6
Online ISBN: 978-3-030-99708-3
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)